Scotiabank lowered the firm’s price target on Geron (GERN) to $4 from $6 and keeps an Outperform rating on the shares. While the company’s Q4 ...

Geron Corp (GERN) reports a robust cash reserve and key FDA approval for Rytelo, but faces flat revenue trends and leadership changes in its commercial strategy.

John Scarlett; Chairman of the Board, President, Chief Executive Officer; Geron Corp Jim Ziegler; Executive Vice President, Chief Commercial Officer; Geron Corp Joseph Eid; Executive Vice President- ...

Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected.

Hello and welcome to the Geron fourth quarter and full year 2024 earnings call. All lines have been placed on mute to prevent any background noise. Aft ...

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Geron ended 2024 with a strong cash position and reported that revenues for the third and fourth quarters exceeded expectations. The company’s net product revenue for RYTELO reached $47.5 million in ...

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m. ET and had been down as much as 38.7% earlier in the ...

Geron (NASDAQ:GERN) stock plunged 30% after management reportedly indicated on the company's Q4 earnings call that sales of ...

Reports Q4 revenue $47.54M, consensus $45.29M. “2024 was a terrific year for Geron (GERN) and for RYTELO, our first-in-class telomerase ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...